A Multicenter, Randomized, Positive Parallel Controlled Clinical Trial of PVE/PVL Combined With DEB-TACE in the Treatment of Large or Large Liver Cancer in the Right Lobe of the Liver Without Hepatectomy
Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
This is a multicenter, randomized, positive parallel controlled clinical study to evaluate the short-term and long-term efficacy and safety of PVL/PVE combined with DEB-TACE in the treatment of unresectable patients with large or large tumors in the right lobe of the liver.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Clinically diagnosed as large or giant hepatocellular carcinoma of the right lobe of the liver;
• Child-Pugh liver function grade A,
• ECOG PS 0-1
• If the tumor is resected with R0, the remaining liver volume is insufficient
• ICG-15R \< 30%
• No serious organic diseases of heart, lung, brain and other organs;
• No history of other malignant tumors;
• The patient's survival time is expected to be more than 3 months.
Locations
Other Locations
China
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITING
Wuhan
Contact Information
Primary
Wan-guang Zhang, M.D.
wgzhang@tjh.tjmu.edu.cn
+8613886195965
Time Frame
Start Date: 2021-12-01
Estimated Completion Date: 2025-06-30
Participants
Target number of participants: 200
Treatments
Active_comparator: Drug-eluting bead transarterial chemoembolization（DEB-TACE)
Percutaneous drug-eluting bead transarterial chemoembolization, followed by conventional transarterial chemoembolization（cTACE) every 2 months. A total of 3 times of chemoembolization will be performed.
Experimental: PVL/PVE+DEB-TACE
PVL and PVE will be performed randomly assigned according to 1:1 according to the random number table.
Related Therapeutic Areas
Sponsors
Leads: Tongji Hospital